EA200600527A1 - Активирующее ppar соединение и содержащая его фармацевтическая композиция - Google Patents
Активирующее ppar соединение и содержащая его фармацевтическая композицияInfo
- Publication number
- EA200600527A1 EA200600527A1 EA200600527A EA200600527A EA200600527A1 EA 200600527 A1 EA200600527 A1 EA 200600527A1 EA 200600527 A EA200600527 A EA 200600527A EA 200600527 A EA200600527 A EA 200600527A EA 200600527 A1 EA200600527 A1 EA 200600527A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- atom
- alkyl
- hydrogen atom
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Соединение, представленное следующей формулой (I):(где каждый из Rи R, которые могут быть одинаковыми или отличаются друг от друга, представляет собой атом водорода, метильную группу или этильную группу; каждый из R, R, Rи R, которые могут быть одинаковыми или отличаются друг от друга, представляет собой атом водорода, атом галогена, нитрогруппу, гидроксильную группу, Cалкильную группу, трифторметильную группу, Cалкоксильную группу, Cалкилкарбонилоксигруппу, ди-Салкиламиногруппу, Cалкилсульфонилоксигруппу, Cалкилсульфонильную группу, Cалкилсульфинильную группу или Cалкилтиогруппу, или Rи R, или Rи Rмогут быть связаны вместе с образованием алкилендиоксигруппы; Х представляет собой атом кислорода, атом серы или N-R(Rпредставляет собой атом водорода, Cалкильную группу, Cалкилсульфонильную группу или Cалкилоксикарбонильную группу); Y представляет собой атом кислорода, C(O)(1 представляет собой число от 0 до 2), карбонильную группу, карбониламиногруппу, аминокарбонильную группу, сульфониламиногруппу или аминосульфонильную группу; Z представляет собой СН или N; n представляет собой число от 1 до 6; и m представляет собой число от 2 до 6) или его соль; и терапевтические лекарственные средства, содержащие любое такое соединение или соль.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49935703P | 2003-09-03 | 2003-09-03 | |
| JP2003317353 | 2003-09-09 | ||
| JP2003364817 | 2003-10-24 | ||
| PCT/JP2004/012750 WO2005023777A1 (ja) | 2003-09-03 | 2004-09-02 | Ppar活性化化合物及びこれを含有する医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200600527A1 true EA200600527A1 (ru) | 2006-08-25 |
| EA009374B1 EA009374B1 (ru) | 2007-12-28 |
Family
ID=34279568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200600527A EA009374B1 (ru) | 2003-09-03 | 2004-09-02 | Активирующее ppar соединение и содержащая его фармацевтическая композиция |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7109226B2 (ru) |
| EP (1) | EP1661890B1 (ru) |
| JP (2) | JP4226005B2 (ru) |
| KR (1) | KR101160808B1 (ru) |
| AU (1) | AU2004270538C1 (ru) |
| BR (1) | BRPI0413991B8 (ru) |
| CA (1) | CA2535749C (ru) |
| CY (1) | CY1111867T1 (ru) |
| EA (1) | EA009374B1 (ru) |
| HR (1) | HRP20110009T1 (ru) |
| IL (1) | IL173639A (ru) |
| MX (1) | MXPA06002435A (ru) |
| NO (1) | NO335823B1 (ru) |
| NZ (1) | NZ545692A (ru) |
| PL (1) | PL1661890T3 (ru) |
| TW (1) | TWI324599B (ru) |
| WO (1) | WO2005023777A1 (ru) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210612B1 (en) * | 2003-06-18 | 2016-10-05 | Ocera Therapeutics, Inc. | Macrocyclic antagonists of the motilin receptor |
| DE602004030344D1 (de) * | 2003-07-31 | 2011-01-13 | Tranzyme Pharma Inc | Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen |
| US7398116B2 (en) | 2003-08-11 | 2008-07-08 | Veran Medical Technologies, Inc. | Methods, apparatuses, and systems useful in conducting image guided interventions |
| US7301033B2 (en) * | 2005-01-27 | 2007-11-27 | Kowa Co., Ltd. | PPAR-activating compound |
| WO2006090768A1 (ja) * | 2005-02-23 | 2006-08-31 | Kowa Co., Ltd. | 光学活性ｐｐａｒ活性化化合物及びその製造中間体の製造法 |
| EP1854779A4 (en) * | 2005-03-01 | 2010-07-21 | Kowa Co | OPTICALLY ACTIVE, PPAR-ACTIVATING COMPOSITE INTERMEDIATE PRODUCT AND MANUFACTURING METHOD THEREFOR |
| US7714141B2 (en) | 2005-05-31 | 2010-05-11 | Kowa Co., Ltd. | Processes for production of optically active PPAR-activating compounds and intermediates for production thereof |
| JP5094392B2 (ja) | 2005-07-28 | 2012-12-12 | 興和株式会社 | 光学活性２−ヒドロキシ酪酸エステルの製造法 |
| US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| WO2008094860A2 (en) | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
| TWI407955B (zh) | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| WO2011037223A1 (ja) | 2009-09-28 | 2011-03-31 | 興和株式会社 | 内臓脂肪重量の低下剤 |
| TWI425948B (zh) * | 2012-01-20 | 2014-02-11 | Compositions for the inhibition or killing of Porphyromonas gingivalis and their use for the alleviation or treatment of periodontal disease and other diseases | |
| KR102098032B1 (ko) * | 2012-09-27 | 2020-04-07 | 교와 가부시키가이샤 | 지질 이상증 치료제 |
| WO2014157607A1 (ja) | 2013-03-29 | 2014-10-02 | 興和株式会社 | ２－ヒドロキシカルボン酸又はその誘導体の光学純度向上法 |
| TWI696462B (zh) | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| MY182468A (en) | 2013-08-28 | 2021-01-25 | Kowa Co | Therapeutic agent for dyslipidemia |
| AU2015204572B2 (en) * | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| TW201618777A (zh) * | 2014-09-26 | 2016-06-01 | 興和股份有限公司 | 脂質異常症治療劑 |
| TWI691331B (zh) | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| WO2017082393A1 (ja) * | 2015-11-12 | 2017-05-18 | 学校法人 聖マリアンナ医科大学 | 緑内障予防治療剤 |
| DK3275438T3 (da) | 2016-07-29 | 2021-01-18 | Kowa Co | Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko |
| JP2019059673A (ja) * | 2016-08-25 | 2019-04-18 | 興和株式会社 | Ｐｂｃの治療剤 |
| KR102671944B1 (ko) * | 2016-08-25 | 2024-06-03 | 코와 가부시키가이샤 | Pbc 의 치료제 |
| CA3047716A1 (en) | 2017-01-11 | 2018-07-19 | Kowa Company, Ltd. | Prophylactic and therapeutic drug for nonalcoholic fatty liver disease |
| US10314825B2 (en) | 2017-02-24 | 2019-06-11 | Kowa Company, Ltd. | Agent for treatment of PBC |
| PL3646867T3 (pl) | 2017-06-30 | 2025-02-17 | Kowa Company, Ltd. | Kompozycja farmaceutyczna |
| WO2019004447A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| US20200121648A1 (en) * | 2017-06-30 | 2020-04-23 | Kowa Company, Ltd. | Pharmaceutical composition |
| JP7402687B2 (ja) * | 2017-06-30 | 2023-12-21 | 興和株式会社 | 医薬組成物 |
| US11419854B2 (en) | 2017-06-30 | 2022-08-23 | Kowa Company, Ltd. | Medicament containing pemafibrate |
| KR20200021481A (ko) * | 2017-06-30 | 2020-02-28 | 교와 가부시키가이샤 | 의약품 |
| WO2019004452A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| KR102512494B1 (ko) | 2017-06-30 | 2023-03-22 | 교와 가부시키가이샤 | 의약 |
| JP6959049B2 (ja) * | 2017-06-30 | 2021-11-02 | 興和株式会社 | 新規低アルブミン血症改善薬 |
| WO2019004451A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
| AU2018393119B2 (en) * | 2017-12-21 | 2022-08-25 | Kowa Company, Ltd. | Methods of treatment of hypertriglyceridemia |
| US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| EP3732168A1 (en) * | 2017-12-27 | 2020-11-04 | Teva Pharmaceuticals International GmbH | Solid state forms of pemafibrate |
| JP7356968B2 (ja) | 2018-05-08 | 2023-10-05 | 国立大学法人 岡山大学 | 心血管疾患に有用な医薬 |
| JP2020105174A (ja) * | 2018-12-27 | 2020-07-09 | 興和株式会社 | 医薬組成物 |
| EP3903781A4 (en) | 2018-12-27 | 2023-01-25 | Kowa Company, Ltd. | PHARMACEUTICAL PREPARATION |
| US20220096443A1 (en) * | 2018-12-27 | 2022-03-31 | Kowa Company, Ltd. | Pharmaceutical composition |
| TWI829841B (zh) * | 2018-12-27 | 2024-01-21 | 日商興和股份有限公司 | 醫藥品 |
| EP4073025B1 (en) | 2019-12-13 | 2024-03-27 | Inspirna, Inc. | Metal salts and uses thereof |
| KR20230172463A (ko) | 2021-04-20 | 2023-12-22 | 교와 가부시키가이샤 | 이상지질혈증 또는 심장혈관병의 예방ㆍ치료를 위한 복합 의약 |
| JPWO2022230920A1 (ru) | 2021-04-28 | 2022-11-03 | ||
| EP4501326A1 (en) | 2022-03-31 | 2025-02-05 | The Jikei University | Therapeutic agent for respiratory disease |
| TW202408499A (zh) | 2022-07-06 | 2024-03-01 | 日商興和股份有限公司 | 降低血中肌肉生長抑制素之藥劑 |
| WO2024014524A1 (ja) | 2022-07-15 | 2024-01-18 | 興和株式会社 | 血中ｌｄｌコレステロール低下剤 |
| WO2024201358A1 (en) * | 2023-03-31 | 2024-10-03 | Ami Lifesciences Private Limited | A process for the preparation of pemafibrate and intermediates thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS593465B2 (ja) * | 1974-06-04 | 1984-01-24 | 藤沢薬品工業株式会社 | チカンアミノアルキルチカンフエノキシカルボンサンルイノ セイゾウホウ |
| JPS6025425B2 (ja) * | 1975-03-06 | 1985-06-18 | 藤沢薬品工業株式会社 | 置換フエノキシ脂肪酸類の合成法 |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| AU2002224139A1 (en) * | 2000-12-05 | 2002-06-18 | Nippon Chemiphar Co. Ltd. | Ppar (peroxisome proliferator activated receptor) activators |
| DE10151390A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| EP1480957A1 (en) * | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars activators |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
-
2004
- 2004-09-02 NZ NZ545692A patent/NZ545692A/xx not_active IP Right Cessation
- 2004-09-02 MX MXPA06002435A patent/MXPA06002435A/es active IP Right Grant
- 2004-09-02 CA CA2535749A patent/CA2535749C/en not_active Expired - Fee Related
- 2004-09-02 WO PCT/JP2004/012750 patent/WO2005023777A1/ja active Application Filing
- 2004-09-02 PL PL04772699T patent/PL1661890T3/pl unknown
- 2004-09-02 EP EP04772699A patent/EP1661890B1/en not_active Expired - Lifetime
- 2004-09-02 HR HR20110009T patent/HRP20110009T1/hr unknown
- 2004-09-02 BR BRPI0413991A patent/BRPI0413991B8/pt not_active IP Right Cessation
- 2004-09-02 KR KR1020067003950A patent/KR101160808B1/ko not_active Expired - Fee Related
- 2004-09-02 JP JP2005513668A patent/JP4226005B2/ja not_active Expired - Lifetime
- 2004-09-02 EA EA200600527A patent/EA009374B1/ru not_active IP Right Cessation
- 2004-09-02 AU AU2004270538A patent/AU2004270538C1/en not_active Ceased
- 2004-09-03 TW TW093126702A patent/TWI324599B/zh not_active IP Right Cessation
- 2004-09-03 US US10/933,467 patent/US7109226B2/en not_active Expired - Lifetime
-
2006
- 2006-02-09 NO NO20060654A patent/NO335823B1/no not_active IP Right Cessation
- 2006-02-09 IL IL173639A patent/IL173639A/en active IP Right Grant
- 2006-04-20 US US11/407,076 patent/US7183295B2/en not_active Expired - Lifetime
-
2008
- 2008-10-31 JP JP2008281020A patent/JP4931893B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-31 CY CY20111100343T patent/CY1111867T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200600527A1 (ru) | Активирующее ppar соединение и содержащая его фармацевтическая композиция | |
| AR058403A1 (es) | PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF. | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| DK1258484T3 (da) | Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler | |
| RU2502730C2 (ru) | Сульфонамидные соединения и их применение | |
| AR044036A1 (es) | Compuestos de pirazolopirimidinas y pirazolopiridinas como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos | |
| EA200401613A1 (ru) | Лекарственное средство для лечения рака | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| CY1110355T1 (el) | Ενεργοποιητης του ενεργοποιουμενου απο πολλαπλασιαστη υπεροξυσωματων υποδοχεα δ | |
| RS51451B (en) | PIRIDINE CARBOXAMIDES AS INHIBITORS OF 11-BETA-HSD1 | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| AR052898A1 (es) | Derivados de la n-[(4,5-difenil -2-tienil) metil] amina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para enfermedades mediadas por los receptores canabinoides cb1 | |
| SE0201937D0 (sv) | Therapeutic agents | |
| HRP20080493T3 (hr) | Supstituirani kinolinski derivati kao mitotski inhibitori kinezina | |
| AR049438A1 (es) | Derivados con estructura aroil-o-piperidina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas | |
| DE602004029355D1 (de) | Sulfopyrrolderivate | |
| SE0300092D0 (sv) | Novel compounds | |
| SE0300091D0 (sv) | Novel compounds | |
| DK1970372T3 (da) | Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler | |
| UY28688A1 (es) | Derivados de amida | |
| HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| RU2008152764A (ru) | Биарилкарбоксиариламиды как модуляторы ванилоидного рецептора типа 1 | |
| EA201000084A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| SE0600134L (sv) | Nya föreningar och användning därav | |
| RU2008139078A (ru) | Производные сульфонил-3-гетероциклилиндазола в качестве лигандов 5-гидрокситриптамина-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |